Neurogene shares are trading higher after HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $45 to $55.
Portfolio Pulse from Benzinga Newsdesk
Neurogene shares surged following an upgrade by HC Wainwright & Co., which maintained a Buy rating and increased the price target from $45 to $55.
March 19, 2024 | 6:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurogene's stock price is expected to experience a positive short-term impact due to the upgraded price target and maintained Buy rating by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors, often leading to immediate stock price reactions. The increase from $45 to $55 represents a substantial uplift in valuation confidence from a reputable analyst firm, likely encouraging both current and potential investors. This positive sentiment is expected to drive short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100